Compstatin |
カタログ番号GC15251 |
13 残基の環状ペプチドであるコンプスタチンは、種特異性を持つ補体系 C3 の強力な阻害剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 206645-99-0
Sample solution is provided at 25 µL, 10mM.
Compstatin is a 13-residue cyclic peptide and a potent inhibitor of the complement system, and has species specificity.
Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans); Compstatin inhibits only the activation of primates' complement system[1].
Compstatin (21 mg/kg) produces complete inhibition when given as a combination of bolus injection and infusion. Compstatin completely inhibits in vivo heparin/protamine-induced complement activation without adverse effects on heart rate or systemic arterial, central venous, and pulmonary arterial pressures[1]. Pig xenografts survival is significantlylonger in the Compstatin perfused group than in the control group. At rejection the biopsy samples obtained from kidneysperfused with Compstatin show less deposition of C3 and fibrin than do the control kidneys[2].
References:
[1]. Soulika AM, et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol. 2000 Sep;96(3):212-21.
[2]. Fiane AE, et al. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 1999 Feb;6(1):52-65.
Animal experiment: | Compstatin-perfused circuit: pig xenografts are perfused with human blood containing Compstatin (final conc. 0.088 mg/mL). Control group: pig kidneys perfused with human blood and control agent. The total fluid volume, protein concentration and amount of blood are equal in both the Compstatin and control perfusion circuits, and the perfusion is performed in both circuits simultaneously with pooled blood from the same two donors. |
References: [1]. Soulika AM, et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol. 2000 Sep;96(3):212-21. |
Cas No. | 206645-99-0 | SDF | |
Chemical Name | 2-((4R,5Z,7S,8Z,10S,11Z,13S,14Z,17Z,19S,20Z,22S,23Z,25S,26Z,28S,29Z,31S,32Z,34R)-10,13-bis((1H-imidazol-5-yl)methyl)-19-((1H-indol-3-yl)methyl)-34-((Z)-((2S,3S)-2-amino-1-hydroxy-3-methylpentylidene)amino)-4-((Z)-(((2S,3R)-1,3-dihydroxy-1-iminobutan-2-yl) | ||
Canonical SMILES | CC[C@]([C@@](N)([H])/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/C/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/1)([H])CCCNC(N)=N)([H])CC2=CN=CN2)([H])CC3=CN=CN3)([H])CC4=CNC5=CC=CC=C45)([H])CC(O)=O)([H]) | ||
Formula | C66H99N23O17S2 | M.Wt | 1550.77 |
溶解度 | Soluble to 2 mg/ml in sterile water | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 0.6448 mL | 3.2242 mL | 6.4484 mL |
5 mM | 0.129 mL | 0.6448 mL | 1.2897 mL |
10 mM | 0.0645 mL | 0.3224 mL | 0.6448 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 13 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *